Advertisement

Advertisement

MIRM Stock Latest News

Mirum Pharmaceuticals Earnings Call Highlights Growth Momentum

Company AnnouncementsMirum Pharmaceuticals Earnings Call Highlights Growth Momentum

PremiumRatings

Mirum Reaffirmed as Top Pick on Zilurgisertib’s Differentiated FOP Profile; Ramakanth Maintains $140 Price Target

4d ago

Mirum sinks after FDA recommends conducing Phase 3 study

PremiumThe Fly

Mirum sinks after FDA recommends conducing Phase 3 study

17d ago

Mirum Pharmaceuticals price target lowered to $123 from $129 at Baird

PremiumThe Fly

Mirum Pharmaceuticals price target lowered to $123 from $129 at Baird

18d ago

Mirum Pharmaceuticals price target lowered to $140 from $145 at TD Cowen

PremiumThe Fly

Mirum Pharmaceuticals price target lowered to $140 from $145 at TD Cowen

18d ago

Mirum Pharmaceuticals price target lowered to $137 from $150 at Morgan Stanley

PremiumThe FlyMirum Pharmaceuticals price target lowered to $137 from $150 at Morgan Stanley

18d ago

Mirum Pharmaceuticals price target lowered to $135 from $148 at RBC Capital

The Fly

Mirum Pharmaceuticals price target lowered to $135 from $148 at RBC Capital

18d ago

Mirum Pharmaceuticals price target lowered to $140 from $185 at H.C. Wainwright

The Fly

Mirum Pharmaceuticals price target lowered to $140 from $185 at H.C. Wainwright

18d ago

Mirum Pharmaceuticals price target lowered to $137 from $146 at Citizens

PremiumThe Fly

Mirum Pharmaceuticals price target lowered to $137 from $146 at Citizens

18d ago

Mirum Pharmaceuticals reports Q2 EPS ($1.06), consensus (75c)

PremiumThe Fly

Mirum Pharmaceuticals reports Q2 EPS ($1.06), consensus (75c)

18d ago

Mirum treatment of primary sclerosing cholangitis granted FDA orphan status

PremiumThe Fly

Mirum treatment of primary sclerosing cholangitis granted FDA orphan status

1M ago

Mirum Advances New Drug Candidate With Fresh Phase 1 Study Update

PremiumCompany Announcements

Mirum Advances New Drug Candidate With Fresh Phase 1 Study Update

1M ago

Arcutis appoints Mirum Pharmaceuticals CEO Christopher Peetz to board

PremiumThe FlyArcutis appoints Mirum Pharmaceuticals CEO Christopher Peetz to board

1M ago

Mirum Pharmaceuticals price target raised to $148 from $142 at RBC Capital

The Fly

Mirum Pharmaceuticals price target raised to $148 from $142 at RBC Capital

2M ago

Mirum Pharmaceuticals price target raised to $125 from $115 at JPMorgan

The Fly

Mirum Pharmaceuticals price target raised to $125 from $115 at JPMorgan

2M ago

Mirum Shareholders Approve Directors, Auditors and Compensation

PremiumCompany Announcements

Mirum Shareholders Approve Directors, Auditors and Compensation

2M ago

Mirum Therapeutics: Strong FOP Data and Priority Review Support Buy Rating and Unchanged $150 Price Target

PremiumRatings

Mirum Therapeutics: Strong FOP Data and Priority Review Support Buy Rating and Unchanged $150 Price Target

2M ago

Buy Rating Reiterated on Mirum Pharmaceuticals as Zilurgisertib Data De-Risk Pipeline; $145 Price Target Unchanged with ~46% Upside Potential

PremiumRatings

Buy Rating Reiterated on Mirum Pharmaceuticals as Zilurgisertib Data De-Risk Pipeline; $145 Price Target Unchanged with ~46% Upside Potential

2M ago

Mirum Pharmaceuticals price target raised to $146 from $140 at Citizens

PremiumThe Fly

Mirum Pharmaceuticals price target raised to $146 from $140 at Citizens

2M ago

Incyte, Mirum announces Phase 2 results from Cohort 1 of Progress study

PremiumThe FlyIncyte, Mirum announces Phase 2 results from Cohort 1 of Progress study

2M ago

Mirum Pharmaceuticals price target raised to $150 from $140 at Morgan Stanley

The Fly

Mirum Pharmaceuticals price target raised to $150 from $140 at Morgan Stanley

2M ago

Vir Biotechnology price target raised to $27 from $23 at Morgan Stanley

The Fly

Vir Biotechnology price target raised to $27 from $23 at Morgan Stanley

2M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >